Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 242

1.

Role of alendronate and risedronate in preventing and treating osteoporosis.

Peters ML, Leonard M, Licata AA.

Cleve Clin J Med. 2001 Nov;68(11):945-51. Review.

PMID:
11718433
2.

Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study.

Rosen CJ, Hochberg MC, Bonnick SL, McClung M, Miller P, Broy S, Kagan R, Chen E, Petruschke RA, Thompson DE, de Papp AE; Fosamax Actonel Comparison Trial Investigators..

J Bone Miner Res. 2005 Jan;20(1):141-51. Epub 2004 Sep 29.

3.

Risedronate: a new oral bisphosphonate.

Umland EM, Boyce EG.

Clin Ther. 2001 Sep;23(9):1409-21. Review.

PMID:
11589256
4.

Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.

Iwamoto J, Takeda T, Sato Y.

Curr Med Res Opin. 2006 May;22(5):919-28. Review.

PMID:
16709313
5.

Health-economic comparison of three recommended drugs for the treatment of osteoporosis.

Brecht JG, Kruse HP, Möhrke W, Oestreich A, Huppertz E.

Int J Clin Pharmacol Res. 2004;24(1):1-10.

PMID:
15575171
6.

Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis.

Sebba AI, Bonnick SL, Kagan R, Thompson DE, Skalky CS, Chen E, de Papp AE; Fosamax Actonel Comparison Trial investigators..

Curr Med Res Opin. 2004 Dec;20(12):2031-41. Erratum in: Curr Med Res Opin. 2005 Feb;21(2):325.

PMID:
15706659
7.

Bisphosphonates for osteoporosis.

[No authors listed]

Drug Ther Bull. 2001 Sep;39(9):68-72. Review.

PMID:
11586803
8.
9.

[Postmenopausal osteoporosis. Bisphosphonates are not all equal].

[No authors listed]

MMW Fortschr Med. 2009 Mar 12;151(11):46-7. German. No abstract available.

PMID:
19469206
10.

Differences in persistence among different weekly oral bisphosphonate medications.

Sheehy O, Kindundu CM, Barbeau M, LeLorier J.

Osteoporos Int. 2009 Aug;20(8):1369-76. doi: 10.1007/s00198-008-0795-8. Epub 2008 Nov 20.

PMID:
19020921
12.

[Osteoporosis therapy. Bisphosphonates compared].

[No authors listed]

MMW Fortschr Med. 2003 Mar 27;145(13):60. German. No abstract available.

PMID:
15101545
13.

14 day endoscopy study comparing risedronate and alendronate in postmenopausal women stratified by Helicobacter pylori status.

Thomson AB, Marshall JK, Hunt RH, Provenza JM, Lanza FL, Royer MG, Li Z, Blank MA; Risedronate Endoscopy Study Group..

J Rheumatol. 2002 Sep;29(9):1965-74.

PMID:
12233894
14.

Common musculoskeletal adverse effects of oral treatment with once weekly alendronate and risedronate in patients with osteoporosis and ways for their prevention.

Bock O, Boerst H, Thomasius FE, Degner C, Stephan-Oelkers M, Valentine SM, Felsenberg D.

J Musculoskelet Neuronal Interact. 2007 Apr-Jun;7(2):144-8.

15.

Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis.

Cramer JA, Amonkar MM, Hebborn A, Altman R.

Curr Med Res Opin. 2005 Sep;21(9):1453-60.

PMID:
16197664
16.

Treatment of osteoporosis with bisphosphonates.

Watts NB.

Rheum Dis Clin North Am. 2001 Feb;27(1):197-214. Review.

PMID:
11285996
17.

Alendronate (Fosamax) and risedronate (Actonel) revisited.

[No authors listed]

Med Lett Drugs Ther. 2005 Apr 25;47(1207):33-5.

PMID:
15843782
18.

Aging bone and osteoporosis: strategies for preventing fractures in the elderly.

Ettinger MP.

Arch Intern Med. 2003 Oct 13;163(18):2237-46. Review.

PMID:
14557222
19.

Changes in bone resorption markers among Japanese patients with postmenopausal osteoporosis treated with alendronate and risedronate.

Takada J, Iba K, Imoto K, Yamashita T.

J Bone Miner Metab. 2007;25(2):142-6. Epub 2007 Feb 26.

PMID:
17323185
20.

[FACT study: benefits of alendronate].

[No authors listed]

MMW Fortschr Med. 2005 Jan 13;147(1-2):52-3. German. No abstract available.

PMID:
15704574

Supplemental Content

Support Center